Sanofi wants to apply for approval for its corona vaccine. Another protein vaccine could soon be available. An alternative for vaccine skeptics?
Paris – The data from studies are positive, said the French pharmaceutical company Sanofi. The Sanofi vaccine offers 100 percent protection against severe courses and hospitalization, according to the company. After a Sanofi booster, the antibody concentration increased by a factor of 18 to 30 compared to the initial situation. In a primary immunization with the Sanofi Corona vaccine, the levels of neutralizing antibodies increased by 84 to 153 times compared to the levels before the booster vaccination. In addition, the corona vaccine was well tolerated by younger and older adults. Now the pharmaceutical company Sanofi and the British manufacturer Glaxo-Smithkline (GSK) want to apply for approval for the jointly developed Covid vaccine.
Sanofi Vaccine Technology: New protein-based Covid-19 vaccine
With the Sanofi vaccine, a second protein-based vaccine should be available in the course of the year in the fight against Corona*. The first protein vaccine from Novavax* has started in Germany. The hoped-for rush was initially a long time coming. The vaccine, which is often incorrectly referred to as a “dead vaccine”, works in a similar way to many flu vaccines. It is a classic principle that Sanofi also uses.
Sanofi’s protein-based vaccine candidate “uses a proven approach that is widely used to prevent infection with other viruses, including pandemic influenza,” explains GSK Vaccines board member Roger Connor. The group therefore hopes that previously unvaccinated people will also be willing to be immunized with the new vaccine. The Sanofi GSK vaccine also contains an effect enhancer, a so-called adjuvant. A drug enhancer is necessary to boost the immune response in the body.
Efficacy of Sanofi-GSK vaccine according to the pharmaceutical companies
- 100 percent effectiveness against severe Covid-19 disease and hospitalization
- 75 percent effectiveness against moderate or severe Covid-19 diseases
- 57.9 percent effectiveness against all symptoms of corona infection – in today’s environment dominated by worrying coronavirus variants.
Sanofi vaccine development setbacks
“No other global phase 3 efficacy study has been conducted with so many variants, including Omicron, during this period,” said Sanofi CEO Thomas Triomphe. After a year’s delay, he now expects the Sanofi vaccine to be introduced soon.
There were setbacks in the development of the corona vaccine: First, the vaccine was administered to study participants in the wrong dose. Then it was difficult for the company to find people for the clinical studies who had never been infected with Corona.
Corona: Approved Covid vaccines in Germany (as of February 2022)
| vaccine | age group | manufacturer | permit |
|---|---|---|---|
| Comirnaty | from 16 | Biontech/Pfizer | December 2020 |
| Comirnaty | from 12 | Biontech/Pfizer | May 2021 |
| Comirnaty | from 5 | Biontech/Pfizer | November 2021 |
| Spikevax | from 18 | Modern Biotech | January 2021 |
| Spikevax | from 12 | Modern Biotech | July 2021 |
| Vaxzevria/ Covid-19 vaccine Astrazeneca | from 18 | Astrazeneca | January 2021 |
| Covid-19 Vacine Janssen | from 18 | Janssen-Cilag/Johnson and Johnson | March 2021 |
| Nuvaxoid | from 18 | Novavax | December 2021 |
The EU already pre-ordered several million doses of the vaccine in the summer of 2020. The vaccine Sanofi is said to play a role as a booster. The vaccine could be used independently of the previously administered vaccines. (ml) *Merkur.de is an offer from IPPEN.MEDIA
